CN114981260A - σ-1受体配体及其用途 - Google Patents

σ-1受体配体及其用途 Download PDF

Info

Publication number
CN114981260A
CN114981260A CN202080086654.4A CN202080086654A CN114981260A CN 114981260 A CN114981260 A CN 114981260A CN 202080086654 A CN202080086654 A CN 202080086654A CN 114981260 A CN114981260 A CN 114981260A
Authority
CN
China
Prior art keywords
hydrochloride
methyl
benzylpiperidin
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080086654.4A
Other languages
English (en)
Chinese (zh)
Inventor
让-雅克·布尔吉尼翁
马丁·施密特
雅克·布里卡德
唐基·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paris Institute For Higher Research Practice
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Universite de Montpellier
Original Assignee
Paris Institute For Higher Research Practice
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paris Institute For Higher Research Practice, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Strasbourg, Universite de Montpellier filed Critical Paris Institute For Higher Research Practice
Publication of CN114981260A publication Critical patent/CN114981260A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080086654.4A 2019-12-19 2020-12-18 σ-1受体配体及其用途 Pending CN114981260A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306705.5 2019-12-19
EP19306705 2019-12-19
PCT/EP2020/086996 WO2021123145A1 (en) 2019-12-19 2020-12-18 Sigma-1 receptor ligands and uses thereof

Publications (1)

Publication Number Publication Date
CN114981260A true CN114981260A (zh) 2022-08-30

Family

ID=69232740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080086654.4A Pending CN114981260A (zh) 2019-12-19 2020-12-18 σ-1受体配体及其用途

Country Status (6)

Country Link
US (1) US20230049619A1 (https=)
EP (1) EP4077310B1 (https=)
JP (1) JP7725475B2 (https=)
CN (1) CN114981260A (https=)
CA (1) CA3157428A1 (https=)
WO (1) WO2021123145A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612371B2 (en) 2019-12-19 2026-04-28 Universite De Strasbourg Sigma-1 receptor ligands and therapeutic uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745077A (zh) * 2003-01-31 2006-03-08 沃泰克斯药物股份有限公司 促旋酶抑制剂及其用途
WO2015064083A1 (en) * 2013-10-29 2015-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2019068771A1 (en) * 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB858792A (en) * 1958-02-10 1961-01-18 Sandoz Ltd New pyridazine derivatives and processes for their manufacture
GB0204252D0 (en) 2002-02-23 2002-04-10 Oxford Glycosciences Uk Ltd Novel compounds
US8404852B2 (en) * 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
ATE522249T1 (de) 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
CA2761279A1 (en) 2009-05-20 2010-11-25 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN102241667B (zh) * 2010-05-14 2013-10-23 中国人民解放军军事医学科学院毒物药物研究所 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745077A (zh) * 2003-01-31 2006-03-08 沃泰克斯药物股份有限公司 促旋酶抑制剂及其用途
WO2015064083A1 (en) * 2013-10-29 2015-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2019068771A1 (en) * 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS

Also Published As

Publication number Publication date
JP2023507508A (ja) 2023-02-22
US20230049619A1 (en) 2023-02-16
EP4077310B1 (en) 2024-05-01
WO2021123145A1 (en) 2021-06-24
EP4077310A1 (en) 2022-10-26
EP4077310C0 (en) 2024-05-01
CA3157428A1 (en) 2021-06-24
JP7725475B2 (ja) 2025-08-19

Similar Documents

Publication Publication Date Title
DK3065738T3 (en) Compositions and Methods for Modulating Farnesoid X Receptors
JP6359560B2 (ja) 複素環式化合物及びその使用方法
TW202341983A (zh) 用於降解突變kras蛋白之化合物及其應用
RU2660897C2 (ru) Новые соединения в качестве ингибиторов гистондеацетилазы 6 и содержащие их фармацевтические композиции
BR112020011779A2 (pt) derivados de sulfonil ureia como moduladores de inflamassona nlrp3
JPH05279357A (ja) アザヘテロサイクリルメチル−クロマン類
JP2002522431A (ja) Ｏｒｌ１レセプターアゴニストとしての２−置換−１−ピペリジルベンゾイミダゾール化合物
CN103917534B (zh) 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物
BR112016011755B1 (pt) Derivado de ureia ou sal farmacologicamente aceitável do mesmo, seu uso e composição farmacêutica que os compreende
KR20120046188A (ko) 신규 화합물, 약제학적 조성물 및 이에 관련된 방법
WO2019241751A1 (en) Ssao inhibitors and uses thereof
FR2738819A1 (fr) Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
JP7725475B2 (ja) シグマ－１受容体リガンド及びその使用
US11339151B2 (en) Aliphatic acid amide derivative
KR20240115832A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
CA3219801A1 (en) Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor
EP4076456B1 (en) Sigma-1 receptor ligands and therapeutic uses thereof
KR20240004819A (ko) 정신 및 신경 질환의 개선, 예방 및/또는 치료를 위한 디아제판 유도체, 이의 제조 방법 및 용도
KR100255619B1 (ko) 신규한 피페리딘 유도체 및 이의 제조방법
JPWO2004080965A1 (ja) ニューロペプチドｆｆ受容体拮抗剤
TWI917344B (zh) 脂肪族酸醯胺衍生物
KR20070036148A (ko) 신경병성 질환의 치료에 적합한 피페리딘, 피페라진 혹은모르폴린의 이량체 화합물 또는 그들의 ７-원 유사체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220830

WD01 Invention patent application deemed withdrawn after publication